|
GPRASP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.82670015067299E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.93653990013354E-13 |
| Normal-vs-Stage2 |
2.3883999999974E-05 |
| Normal-vs-Stage3 |
2.21400009436934E-10 |
| Normal-vs-Stage4 |
2.56119569996827E-11 |
| Stage1-vs-Stage2 |
2.180000E-01 |
| Stage1-vs-Stage3 |
2.593000E-01 |
| Stage1-vs-Stage4 |
2.834200E-02 |
| Stage2-vs-Stage3 |
5.516200E-02 |
| Stage2-vs-Stage4 |
1.074060E-02 |
| Stage3-vs-Stage4 |
3.139200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.24239951659888E-10 |
| Normal-vs-AfricanAmerican |
9.522800E-03 |
| Normal-vs-Asian |
3.86910004035457E-09 |
| Caucasian-vs-AfricanAmerican |
1.138410E-02 |
| Caucasian-vs-Asian |
6.498200E-01 |
| AfricanAmerican-vs-Asian |
6.992200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.43900036120704E-10 |
| Normal-vs-Female |
1.63691282750733E-12 |
| Male-vs-Female |
5.290600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.5498997598753E-10 |
| Normal-vs-Age(41-60Yrs) |
8.20732370954147E-12 |
| Normal-vs-Age(61-80Yrs) |
1.91530002968676E-09 |
| Normal-vs-Age(81-100Yrs) |
1.237290E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.332200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.423000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.107000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.295200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.359400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.214800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.371500E-04 |
| Classical-VS-Follicular |
5.750200E-01 |
| Classical-VS-Other |
5.168400E-01 |
| Classical-VS-Normal |
5.57210000362574E-09 |
| Tall-VS-Follicular |
1.178660E-03 |
| Tall-VS-Other |
3.803800E-01 |
| Tall-VS-Normal |
1.82320825103943E-12 |
| Follicular-VS-Other |
4.794000E-01 |
| Follicular-VS-Normal |
1.95220000054341E-07 |
| Other-VS-Normal |
3.635500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.55846513051029E-12 |
| Normal-vs-N1 |
5.5907500851049E-12 |
| N0-vs-N1 |
2.676200E-03 |
|
|
